Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from SARS-CoV-2 neutralising antibody profiles reveal variant specific antibody dynamics and regional differences in infection histories in Malawi. Local targets link to admitted publications; unresolved targets remain external evidence.
Undetected COVID-19 cases in Africa
10.1016/s2213-2600(21)00504-x · 2021 · External reference
Unresolved reference
External reference
Viral ribonucleic acid shedding and transmission potential of asymptomatic and paucisymptomatic coronavirus disease 2019 patients
10.1093/ofid/ofaa599 · 2020 · External reference
SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021
10.1136/bmjgh-2022-008793 · 2022 · External reference
Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: a population-based cohort study
10.1016/j.ijid.2023.10.020 · 2023 · External reference
Controlling the first wave of the COVID-19 pandemic in Malawi: Results from a multi-round study
10.1371/journal.pgph.0003474 · 2024 · External reference
Lockdown measures in response to COVID-19 in nine sub-Saharan African countries
10.1136/bmjgh-2020-003319 · 2020 · External reference
SARS-CoV-2 prevalence and immunity: a hospital-based study from Malawi
10.1016/j.ijid.2021.12.336 · 2022 · External reference
SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021
10.1186/s12916-021-02187-y · 2021 · External reference
Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi
10.1016/j.eclinm.2022.101800 · 2023 · External reference
Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population
10.1038/s41467-024-44973-1 · 2024 · External reference
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
10.1126/sciimmunol.abq4450 · 2022 · External reference
Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1
10.1016/s2666-5247(22)00384-6 · 2023 · External reference
Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron
10.1016/j.immuni.2022.07.018 · 2022 · External reference
Mapping SARS-CoV-2 antigenic relationships and serological responses
10.1126/science.adj0070 · 2023 · External reference
Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: A mathematical modelling study
10.1016/s1473-3099(24)00484-5 · 2025 · External reference
An open source tool to infer epidemiological and immunological dynamics from serological data: serosolver
2020 · External reference
Reconstructed influenza A/H3N2 infection histories reveal variation in incidence and antibody dynamics over the life course
2024 · External reference
Estimation of seasonal influenza attack rates and antibody dynamics in children using cross-sectional serological data
10.1093/infdis/jiaa338 · 2022 · External reference
SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron’s impact in South African population cohorts
2022 · External reference
Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels
10.1038/s41467-021-26452-z · 2021 · External reference
Long-term monitoring of SARS-CoV-2 seroprevalence and variants in Ethiopia provides prediction for immunity and cross-immunity
10.1038/s41467-024-47556-2 · 2024 · External reference
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial
10.1038/s41467-024-53727-y · 2024 · External reference
Characterising protective immune responses to SARS-CoV-2 in urban and rural Malawi between February 2021 and April 2022
10.1038/s41598-025-22599-7 · 2025 · External reference
Severe acute respiratory syndrome coronavirus 2 serosurveillance in a patient population reveals differences in virus exposure and antibody-mediated immunity according to host demography and healthcare setting
10.1093/infdis/jiaa788 · 2021 · External reference
10.32614/cran.package.epitools
10.32614/cran.package.epitools · External reference
Reconstructing antibody dynamics to estimate the risk of influenza virus infection
10.1038/s41467-022-29310-8 · 2022 · External reference
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
10.1038/s41564-022-01143-7 · 2022 · External reference
Unresolved reference
External reference
COVID-19 testing in Africa: Lessons learnt
10.1016/s2666-5247(20)30068-9 · 2020 · External reference
The challenges of SARS-CoV-2 testing in low- and middle-income countries and possible cost-effective measures in resource-limited settings
10.1186/s12992-022-00796-7 · 2022 · External reference
Neutralizing antibody titres in SARS-CoV-2 infections
10.1038/s41467-020-20247-4 · 2021 · External reference
Neutralizing antibody responses in COVID-19 convalescent sera
10.1093/infdis/jiaa673 · 2021 · External reference
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
10.1038/s41467-022-32396-9 · 2022 · External reference
Increase in SARS-CoV-2 seroprevalence in UK domestic felids despite weak immunogenicity of post-omicron variants
10.3390/v15081661 · 2023 · External reference
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
10.1126/science.abq1841 · 2022 · External reference
Immune imprinting and protection against repeat reinfection with SARS-CoV-2
10.1056/nejmc2211055 · 2022 · External reference
Trichinella spiralis infection inhibits the efficacy of RBD protein of SARS-CoV-2 vaccination via regulating humoral and cellular immunity
10.3390/vaccines12070729 · 2024 · External reference
IPSE/alpha-1: a major immunogenic component secreted from Schistosoma mansoni eggs
10.1016/j.molbiopara.2006.01.003 · 2006 · External reference
Tracking the evolution of serum antibody levels and influencing factors post-SARS-CoV-2 infection among community residents in Fuzhou City
10.3389/fimmu.2025.1533102 · 2025 · External reference
Association of age with SARS-CoV-2 antibody response
2021 · External reference
Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients
10.1002/jmv.26939 · 2021 · External reference
Association between population density and infection rate suggests the importance of social distancing and travel restriction in reducing the COVID-19 pandemic
10.1007/s11356-021-12364-4 · 2021 · External reference
Correlation between population density and COVID-19 cases during the third wave in Malaysia: Effect of the delta Variant
10.3390/ijerph19127439 · 2022 · External reference
COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron)
10.7554/elife.78933 · 2022 · External reference
Anti-spike antibody response to natural SARS-CoV-2 infection in the general population
10.1038/s41467-021-26479-2 · 2021 · External reference
